Back
  1. Home
  2. Profile of Manon Degey (ULiège)
Profil

Degey Manon

Département de pharmacie > Développement de nanomédicaments

CIRM

See author's contact details
ORCID
0009-0002-9691-7210
Main Referenced Co-authors
Berger, Manon  (16)
Evrard, Brigitte  (16)
Piel, Géraldine  (16)
Maquoi, Erik  (10)
Debuigne, Antoine  (6)
Main Referenced Keywords
LNP (4); lipid-PEG (3); protein corona (3); LNPs (2); NTA (2);
Main Referenced Unit & Research Centers
CIRM - Centre Interdisciplinaire de Recherche sur le Médicament - ULiège (5)
Main Referenced Disciplines
Pharmacy, pharmacology & toxicology (16)
Biochemistry, biophysics & molecular biology (1)

Publications (total 17)

The most downloaded
140 downloads
Degey, M., Berger, M., Evrard, B., & Piel, G. (10 April 2024). Exploring alternatives to PEG for the formulation of lipid nanoparticles encapsulating siRNA [Poster presentation]. 17th European Symposium on Controlled Drug Delivery. https://hdl.handle.net/2268/316320

The most cited

59 citations (OpenAlex)

Berger, M., Degey, M., Leblond Chain, J., Maquoi, E., Evrard, B., Lechanteur, A., & Piel, G. (10 February 2023). Effect of PEG Anchor and Serum on Lipid Nanoparticles: Development of a Nanoparticles Tracking Method. Pharmaceutics, 15 (2). doi:10.3390/pharmaceutics15020597 https://hdl.handle.net/2268/299970

Degey, M., Berger, M., Stephan, R., Hego, A., Ormenese, S., Evrard, B., Piel, G., & Maquoi, E. (30 January 2026). A multiparametric kinetic in vitro assay for siRNA–LNP efficacy and toxicity: live-cell imaging cross-validated with flow cytometry [Paper presentation]. CIRM DAY.

Puttemans, J.* , Brammerloo, Y.* , Blibek, K., Blavier, J., Ntombela, T., Van Molle, I., Joseph, J., Olivet, J., Saha, D., Degey, M., Hamaïdia, M., Jain, P., Geraldine, P., Zimmermann, P., Kim, D.-K., Baiwir, D., Njock, M.-S., Dequiedt, F., Salehi-Ashtiani, K., ... Maseko, S. B.*. (August 2025). Inhibitors of Tax1-PDZ Interactions Block HTLV-1 Viral Transmission by Changing EV Composition. Journal of Extracellular Vesicles, 14 (8), 70137. doi:10.1002/jev2.70137
Peer Reviewed verified by ORBi
* These authors have contributed equally to this work.

Berger, M., Degey, M., Curnel, A., Evrard, B., & Piel, G. (2025). The benefits of emerging alternatives to PEG for lipid nanoparticle RNA delivery systems. Nanomedicine, 1 - 3. doi:10.1080/17435889.2025.2500917
Peer Reviewed verified by ORBi

Curnel, A., Degey, M., Evrard, B., Piel, G., & Berger, M. (31 March 2025). Production and characterization of lipid nanoparticle formulations with different ionizable lipids in order to compare their cell efficacy and toxicity [Paper presentation]. 22nd Forum of Pharmaceutical Sciences, La Roche-en-Ardenne, Belgium.
Editorial reviewed

Degey, M., Berger, M., Debuigne, A., Jérôme, C., Evrard, B., Maquoi, E., Leblond Chain Jeanne, & Piel, G. (29 January 2025). ADVANCING siRNA DELIVERY: DSPE-PNMVA AS A SOLUTION TO THE PEG DILEMMA IN LNP [Paper presentation]. CIRM DAY, Liège, Belgium.

Degey, M., Berger, M., Meloni, L., Pedergnana, S., Debuigne, A., Jérôme, C., Evrard, B., Maquoi, E., Leblond Chain Jeanne, & Piel, G. (2025). Redesigning lipid nanoparticles for enhanced intravenous delivery for cancer treatment: PNMVA as a promising PEG substitute [Poster presentation]. 5th Conference on Innovation in Drug Delivery, Turin, Italy.

Degey, M., Berger, M., Meloni, L., Pedergnana, S., Debuigne, A., Jérôme, C., Evrard, B., Maquoi, E., Leblond Chain Jeanne, & Piel, G. (2025). Redefining PEGylation: PNMVA-driven innovation in lipid nanoparticle delivery for cancer therapy [Poster presentation]. ESCGT, Séville, Spain.

Degey, M., Berger, M., Meloni, L., Pedergnana, S., Debuigne, A., Jérôme, C., Evrard, B., Maquoi, E., Leblond Chain Jeanne, & Piel, G. (2025). Beyond PEGylation: PNMVA as a novel driver of lipid nanoparticle advances in cancer therapy [Poster presentation]. Biomaterial Day.

Degey, M., Meloni, L., Penoy, N., Sacre, P.-Y., Berger, M., Dede, B., Guerreiro Inês, Evrard, B., Leblond Chain Jeanne, Piel, G., & Maquoi, E. (2025). Optimizing siRNA-loaded lipid nanoparticle lyophilization through QbD approach with stability characterization [Poster presentation]. Biomaterial Day.

Degey, M., Berger, M., Debuigne, A., Jérôme, C., Evrard, B., Leblond Chain Jeanne, & Piel, G. (03 December 2024). ADVANCING siRNA DELIVERY: DSPE-PNMVA24 AS A SOLUTION TO THE PEG DILEMMA IN LNP FOR TUMOR TARGETING [Poster presentation]. SF Nano.

Degey, M., Berger, M., Debuigne, A., Jérôme, C., Evrard, B., Leblond Chain, J., & Piel, G. (28 October 2024). Impact of lipid-polymer type and content on Lipid Nanoparticles (LNPs) physico-chemical properties and protein corona formation [Poster presentation]. CRS BNLF Local Chapter, Gand, Belgium.

Degey, M., Berger, M., Evrard, B., & Piel, G. (10 April 2024). Exploring alternatives to PEG for the formulation of lipid nanoparticles encapsulating siRNA [Poster presentation]. 17th European Symposium on Controlled Drug Delivery.

Degey, M., Berger, M., Evrard, B., & Piel, G. (31 January 2024). New amphiphilic polymers with variable length and number of lipid chains as alternatives to PEG for the formulation of lipid nanoparticles encapsulating siRNA [Poster presentation]. CIRM DAY - Scientific day, Liege, Belgium.

Berger, M., Degey, M., Leblond Chain, J., Maquoi, E., Evrard, B., Lechanteur, A., & Piel, G. (27 April 2023). Effect of PEG anchor and serum on Lipid Nanoparticles: development of a nanoparticle tracking method [Paper presentation]. 21st Forum of Pharmaceutical Sciences, Blankenberge, Belgium.

Berger, M., Degey, M., Leblond Chain, J., Maquoi, E., Evrard, B., Lechanteur, A., & Piel, G. (21 March 2023). Impact of the hydrophobic chain length of PEG derivatives on the behavior of LNPs in serum: Development of a Nanoparticle Tracking Analysis (NTA) Method [Poster presentation]. 4th European Conference on Pharmaceutics, Marseille, France.
Peer reviewed

Berger, M., Degey, M., Leblond Chain, J., Maquoi, E., Evrard, B., Lechanteur, A., & Piel, G. (10 February 2023). Effect of PEG Anchor and Serum on Lipid Nanoparticles: Development of a Nanoparticles Tracking Method. Pharmaceutics, 15 (2). doi:10.3390/pharmaceutics15020597
Peer Reviewed verified by ORBi

Berger, M., Degey, M., Leblond Chain, J., Maquoi, E., Evrard, B., Lechanteur, A., & Piel, G. (01 February 2023). Effect of PEG anchor and serum on Lipid Nanoparticles: development of a nanoparticles tracking method [Paper presentation]. CIRM Day, Liege, Belgium.

Contact ORBi